🇺🇸

US SEC Filing Intelligence

· daily

NASA & Space Contracts Intelligence — September 05, 2026

NASA awarded Blue Origin, LLC a $660,000,017 firm-fixed-price contract for the Mars Sample Return mission and future Mars exploration, marking a significant civilian space win for the company. This is the sole contract in the period, entirely civilian (0/1 defense-related), with a strong bullish signal (7/10). The award underscores NASA's sustained commitment to deep-space infrastructure, but the fixed-price structure and lack of initial funding outlay introduce execution and budget risks. Blue Origin's competitive win in a full-and-open competition signals its growing capability in deep-space systems, though investors should monitor milestone progress and NASA budget dynamics closely.

1 total filings
· daily

Mega Contracts Monitor ($100M+) — September 05, 2026

This digest covers $1.49 billion in total obligations across four contracts, with only one defense-related award (25% of total), signaling a civilian-heavy procurement period dominated by NASA's $660 million Mars Sample Return contract to Blue Origin. The highest-conviction signal is bullish for Blue Origin's competitive win in deep-space exploration, though the fixed-price structure and zero initial outlay pose execution risk. Civilian contracts from GSA and DHS total $827 million, but legacy awards from 2017-2018 (GDIT, PAE) offer limited forward visibility. Key risks include fixed-price margin pressure on Blue Origin and Integrated Quality Solutions, and budget uncertainty for NASA's Mars program.

4 total filings
· daily

High-Value Federal Grants ($5M+) — September 05, 2026

This digest covers $1.487 billion in total obligations across four contracts, with only one (25%) defense-related award, underscoring a civilian-heavy procurement theme. The highest-conviction signal is Blue Origin's $660 million NASA Mars Sample Return contract, a bullish deep-space exploration win that strengthens its competitive moat but carries high fixed-price execution risk. The remaining three contracts—General Dynamics IT ($440M, legacy NAVAIR engineering), Amentum/PAE ($224M, USCIS application support), and Integrated Quality Solutions ($162M, GSA pharmaceutical logistics)—are neutral signals with limited forward-looking impact due to maturing periods or fixed-price margin pressure. Key risk: Blue Origin's contract has zero funds outlayed, making it vulnerable to NASA budget reallocations or CR delays.

4 total filings
· daily

General Federal Contracts — September 05, 2026

This digest covers $1.487 billion in federal contracts awarded between 2017 and 2026, with only one of four contracts defense-related (General Dynamics Information Technology's $440M NAVAIR engineering services award), indicating a civilian-heavy period. The dominant theme is NASA's deep-space exploration push, led by Blue Origin's $660M firm-fixed-price Mars Sample Return contract—the highest-conviction signal despite execution risk from zero initial funding. Key risks include fixed-price pressure on Blue Origin and Integrated Quality Solutions, and legacy contract maturity for GDIT. Investors should watch NASA budget stability and Blue Origin's milestone progress as primary catalysts.

4 total filings
· daily

All NASA Contracts — September 05, 2026

This digest covers a single, high-materiality NASA contract awarded to Blue Origin, LLC valued at $660 million for Mars Sample Return and exploration missions. The total obligation is entirely civilian (NASA), with no defense-related spending. The dominant theme is deep-space exploration infrastructure, and the highest-conviction signal is Blue Origin's competitive win in a full-and-open competition, strengthening its position against rivals. Key risks include the fixed-price contract structure with no initial funds outlayed, execution milestones, and potential NASA budget cuts to the Mars Sample Return program.

1 total filings
· daily

Biotech Small-Cap Approvals — September 04, 2026

The September 4, 2026 approval digest contains 5 biosimilar/other approvals and zero NMEs, zero biosimilars (by formal designation), and zero label expansions, tilted entirely toward generic competition in mature drug classes. Two sponsors—DR REDDYS and SPIL—received simultaneous biosimilar/other approval for POMALIDOMIDE, a multiple myeloma therapy originally commercialized by BRISTOL MYERS SQUIBB, signaling an aggressive wave of multiple entrant competition. The digest lacks any high-value NME or breakthrough therapy catalysts, and all approvals are rated neutral/5/10, providing no sector-moving bullish or bearish signals. Investors should watch for accelerated revenue erosion for originator Pomalyst/Imnovid as two ANDA players enter the market, and for TEVA PHARM’s entry into the elagolix+estrogen franchise (originally AbbVie’s Orilissa), a signal of incremental generic pressure in endometriosis therapeutics. The single-period concentration on pomalidomide generics warrants a cautious near-term posture on Bristol Myers Squibb’s hematology revenue stream.

5 total filings
· daily

New Drug Approvals (Original) — September 04, 2026

The September 4, 2026, FDA new drug approval stream recorded five approvals, all classified as 'FALLBACK' (likely generic/biosimilar follow-ons), with zero NMEs, zero novel biosimilars, and zero label expansions. The dominant theme is generic/biosimilar competition in established therapeutic categories: two approvals of POMALIDOMIDE (Dr. Reddy’s / SPIL) create a direct threat to the originator (Bristol Myers Squibb’s POMALYST), and one approval of ELAGOLIX/estradiol/norethindrone acetate (Teva) challenges AbbVie’s ORILISSA franchise. Qilu Pharma’s DIFELIKEFALIN ACETATE and Macleods’ MAGNESIUM SULFATE are niche generic entries. The highest-conviction signal is the dual POMALIDOMIDE approval, accelerating generic erosion of a $700M+ oncology asset. Key risk: investor overexposure to BMS’s POMALYST revenue stream, and AbbVie’s ORILISSA facing new low-cost competition. No IRA exposure flags are triggered from these specific approvals, but the data confirms ongoing margin compression in small-molecule oncology and women’s health segments.

5 total filings
· daily

Federal Construction & Infrastructure Contracts — September 04, 2026

The sole contract in this digest is a $484.2 million firm-fixed-price award from the Department of State to Caddell Construction Co. (DE), LLC for the design-build of the U.S. Embassy in Ulaanbaatar, Mongolia, representing a civilian (non-defense) infrastructure investment. This large, competitively won contract signals a stable revenue stream for Caddell over roughly 5.3 years, but the firm-fixed-price structure and complex foreign construction expose the company to execution risk. The highest-conviction signal is the revenue visibility, while the key watch item is Caddell's margin performance and project milestones given the high-risk pricing model.

1 total filings
· daily

New Federal Contractors — September 04, 2026

The six contracts analyzed total $1.34 billion in obligations, with a civilian-heavy split (4 of 6 contracts, ~$1.33B) versus defense-related awards (2 of 6, ~$222M). The dominant theme is federal investment in infrastructure and IT services, led by a $484.2M State Department embassy construction award to Caddell Construction and a $357.9M USAID trade initiative contract to DAI Global. The highest-conviction signal is Caddell's large, competitively won fixed-price contract, which offers a multi-year revenue stream but carries execution risk. Key watch items include the potential recompetition of ATCC's expired NIH biodefense repository contract and the unusual negative outlay on ManTech's GSA network defense award.

6 total filings
· daily

Significant Contract Modifications ($10M+) — September 04, 2026

The six contracts analyzed, totaling $1.34B in obligations, are overwhelmingly civilian (4 of 6), with only two defense-related awards (Lockheed Martin at $1.5M and a DHS Coast Guard contract). The dominant theme is State Department and USAID infrastructure and development spending, led by Caddell Construction's $484M embassy build in Mongolia and DAI Global's $358M trade initiative. The highest-conviction signal is Caddell's full-and-open competitive win on a large firm-fixed-price contract, which carries execution risk on a complex overseas project. A key risk is the expired or underperforming status of several contracts (ATCC, Guidehouse, ManTech), suggesting limited current revenue visibility from these awards. Investors should watch for recompete announcements for the ATCC biodefense repository and ManTech's E DEFEND network defense program as potential catalysts.

6 total filings
· daily

Contract Deobligations Alert — September 04, 2026

This digest of 6 contract actions totaling $1.34 billion shows a **dominant civilian agency tilt**, with 4 of 6 awards from State, USAID, HHS, and GSA, and only 2 defense-related (DHS Coast Guard being the smaller). The **highest-conviction signal** is Caddell Construction's $484 million firm-fixed-price contract for the U.S. Embassy in Mongolia—a large, competitively won civilian infrastructure award that provides ~$91M annual revenue visibility through 2032, but carries high execution risk given the fixed-price design-build complexity in a remote location. **Key watch item**: ManTech's E DEFEND cybersecurity contract (GSA) shows a negative outlayed amount (-$371K) that may signal accounting adjustments or prior overbillings, warranting scrutiny ahead of the contract's April 2024 end date and potential recompete. Overall, the digest underscores stable civilian diplomatic and health IT spending, with no purely defense expansion plays and no bullish or bearish signals recorded.

6 total filings
· daily

Contract Option Exercises — September 04, 2026

The six contract option exercises reviewed total $1.34 billion in obligations, with only two defense-related awards (Lockheed Martin's $1.5M Coast Guard order and MANTECH's $220.9M GSA network defense order), underscoring a predominantly civilian-focused procurement stream. The dominant theme is federal infrastructure and technology investment, led by a $484.2M State Department embassy construction award to Caddell Construction and a $357.9M USAID trade initiative to DAI Global. The highest-conviction signal is Caddell's competitive win, which provides a multi-year revenue stream but carries high execution risk under a firm-fixed-price structure. Key risks include the negative outlayed amount on MANTECH's contract and the expired status of ATCC and Guidehouse contracts, which limit current revenue visibility. Investors should monitor re-competes and option exercises, particularly for ATCC's biodefense repository and MANTECH's E DEFEND program.

6 total filings
· daily

Federal IT & Cybersecurity Contracts — September 04, 2026

The two contracts analyzed total $351.1 million in obligations, with a 50/50 split between defense and civilian agencies. The dominant theme is federal IT and cybersecurity services, led by a $220.9 million GSA award to MANTECH for network defense support, which provides a stable, recurring revenue stream through April 2024. The second contract, a $130.2 million NIH award to Guidehouse Digital for bioinformatics software support, is now expired, limiting current revenue visibility. The highest-conviction signal is MANTECH's competitive win under full-and-open competition, signaling strong positioning in the federal cybersecurity market. A key risk is the negative outlayed amount on the MANTECH contract, which may indicate accounting adjustments or prior overpayments, warranting close monitoring of revenue recognition.

2 total filings
· daily

All HHS Contracts — September 04, 2026

The two HHS contracts analyzed total $271.2M in obligations, both civilian (0% defense-related), with a neutral average signal strength of 5.5/10. The dominant theme is NIH/NIAID-funded biodefense and biomedical research infrastructure, led by a $141M cost-plus-fixed-fee contract to American Type Culture Collection (ATCC) for biological repository services. The highest-conviction signal is ATCC's incumbent position in a critical biodefense repository (MID BRR), though the contract has ended with only $63.5M outlayed, implying potential underperformance or scope reduction. A key risk is that both contracts are expired (2022 and 2023), offering no current revenue streams, making follow-on recompetes the primary catalysts to monitor.

2 total filings
· daily

Mega Contracts Monitor ($100M+) — September 04, 2026

This digest covers $1.33 billion in new obligations across five mega-contracts ($100M+) awarded between 2016 and 2026, with only 2 of 5 being defense-related (GSA and State), signaling a civilian-heavy week for large awards. The dominant theme is diplomatic infrastructure and international development, led by a $484.2M firm-fixed-price embassy construction contract to CADDELL CONSTRUCTION CO. (DE), LLC and a $357.9M USAID cost-plus contract to DAI GLOBAL LLC. The highest-conviction signal is the Caddell award—material at 7/10—but it carries high execution risk due to its fixed-price nature on a complex foreign project. Key risk: the $220.9M MANTECH ADVANCED SYSTEMS INTERNATIONAL, INC. GSA contract shows a negative outlayed amount (-$371K), flagging potential accounting issues or prior overpayments. No bullish or bearish signals were identified; all five contracts are rated neutral, reflecting a mixed, low-conviction week for investors.

5 total filings
· daily

High-Value Federal Grants ($5M+) — September 04, 2026

This digest covers $1.33 billion in aggregate obligations across five high-value federal contracts, with a 2/5 defense-related split (40% defense, 60% civilian). The dominant theme is civilian infrastructure and services: the Department of State’s $484.2M embassy construction award to CADDELL CONSTRUCTION CO. (DE), LLC is the highest-conviction signal, representing a stable ~$91M annual revenue stream over 5.3 years, albeit with high execution risk due to firm-fixed-price pricing on a complex foreign project. The remaining contracts are neutral, with low pricing risk but limited near-term upside: DAI Global LLC’s $357.9M USAID award, MANTECH’s $220.9M GSA cybersecurity delivery order, ATCC’s $141M NIH biodefense repository (now expired), and Guidehouse Digital’s $130.2M NIH software support (also expired). Key risk: the two largest civilian contracts (ATCC and Guidehouse) have ended, creating revenue gaps for those entities. No bullish or bearish signals were identified; all five contracts are neutral. Investors should monitor re-compete opportunities for ATCC and Guidehouse, and track CADDELL’s margin performance on the Mongolia embassy project.

5 total filings
· daily

General Federal Contracts — September 04, 2026

This digest covers five contracts totaling $1.33 billion, with a civilian-heavy tilt (3/5 civilian agencies, 2/5 defense-related). The Department of State’s $484.2 million firm-fixed-price award to Caddell Construction for the Ulaanbaatar embassy is the highest-conviction signal, offering a predictable ~$91.4M annual revenue stream but carrying elevated execution risk on a complex foreign project. The remaining contracts are lower-risk cost-plus or labor-hour awards to DAI Global, ManTech, ATCC, and Guidehouse Digital, but several are expired or nearing expiration, limiting current revenue visibility. Key watch items include Caddell’s margin performance on the embassy build and the re-compete of ATCC’s NIH biodefense repository contract.

5 total filings
· daily

S&P 500 Technology Sector SEC Filings — September 04, 2026

The September 4, 2026 batch of S&P 500 Technology filings reveals a stark insider selling pattern concentrated in high-growth software names, with Datadog's entire C-suite liquidating approximately $24.6M in stock at $212.90 per share, while CrowdStrike's CEO executed a 10b5-1 plan for $649K. This broad-based insider selling, combined with a Salesforce director's $803K sale, signals potential valuation concerns or profit-taking at elevated levels. The filings lack period-over-period financial comparisons, forward guidance, or capital allocation changes, making the insider activity the dominant actionable signal. The sector appears to be in a 'show-me' phase where management teams are reducing exposure despite likely strong operational performance, creating a tactical caution flag for growth investors.

12 high priority 12 total filings
· daily

Nasdaq 100 Stocks SEC Filings — September 04, 2026

The three NASDAQ-100 filings (ADP, Mondelez, NVIDIA) reveal a quiet insider trading day with no material period-over-period trends, forward-looking guidance, or capital allocation changes to synthesize. The dominant theme is insider activity, but it is largely non-actionable: ADP's EVP sold a small amount under a 10b5-1 plan (no conviction signal), Mondelez's COO had shares withheld for taxes after an option exercise (a routine, neutral event), and NVIDIA's director made a large gift of 500,000 shares (a planned transfer, not a market sale). No company reported financial results, guidance updates, or strategic transactions. The lack of any bullish or bearish operational data means the digest is heavily weighted toward risk and opportunity identification from the insider patterns themselves. The most critical development is the NVIDIA gift, which, while neutral in sentiment, represents a significant reduction in direct holdings by a long-tenured director and warrants monitoring for any acceleration of insider selling. Overall, the filing set provides minimal actionable intelligence for active portfolio decisions today.

3 high priority 3 total filings
· daily

US Activist Hedge Fund Institutional SEC 13D 13G — September 04, 2026

This batch of 50 filings reveals a significant shift in activist and institutional activity, with a notable increase in passive-to-active conversions and large strategic stake accumulations. The most critical development is the Tether/Rumble filing, where Tether now holds a 50.3% controlling stake, signaling a major strategic move in the digital media space. We also see a pattern of institutional investors fully exiting SPAC positions (Magnetar Financial exiting 7 SPACs), while other entities like BlueArc Capital and Grey Rock are building or maintaining large, controlling stakes. Insider activity is mixed: the CEO of Addex Therapeutics repriced options to a near-zero strike price, signaling deep insider alignment but also highlighting severe share price decline, while Lantheus is actively selling its Perspective Therapeutics stake. Period-over-period comparisons are limited in these filings, but the data shows a clear trend of large, strategic block acquisitions and a rotation away from passive SPAC exposure. The most actionable insights center on the Tether/Rumble control, the GeoPark/Gilinski transaction, and the VolitionRx activist campaign.

12 high priority 38 medium 50 total filings